Reshaping the narrative on biopharma innovation with BIO Board Chair Dr. Ted Love

Mainstage at the GA Life Sciences Summit

Dovetailing closely on access, advocacy, policy and innovation, BIO Board Chair and founder of Global Blood Therapeutics Dr. Ted Love discussed his mission oriented journey in the life sciences in the day’s keynote. This work continues with the need to reshape the narrative around biopharma innovation, access, cost and value.

“Drug cost is not a singular item,” Dr. Love told GRA Senior Advisor Greg Vaughn, MD in their post remarks chat. “We need to get copays out of the system and stop blocking egregious things we do to discourage patients from taking medicines.”

Our recent weekly bioBEAT summarized Dr. Love’s keynote thusly: 

“BIO Board Chair Dr. Ted Love founded a company (Global Blood Therapeutics—since acquired by Pfizer ) to develop treatments for sickle cell disease, so he is solidly grounded in the biopharma space. However, he’s enthusiastic about biotech’s potential to help achieve a wide range of societal goals. At Georgia Bio’s Life Sciences Summit this week, Ted spoke about the importance of communicating biotech’s full potential and opening minds to the promise of innovation.

“‘Showing the public how we change lives through innovations is a huge task that we must all embrace!’ he said in his remarks. ‘But, we can do this by telling everyone we talk to [that] biotechnology is our only hope – to fight egregious diseases and future pandemics, to produce clean energy to fight climate change, to solve food insecurity , and to provide biodefense to keep us all secure.’

“Ted shared a story about his own daughter’s (Alex) skepticism toward the biopharma industry—until she spent one summer working at Global Blood Therapeutics and saw firsthand how impactful the company’s work could be for patients. ‘Perhaps we can learn a lesson from my experience with Alex when it comes to reframing the narrative of our industry,’ he said.

“‘We need to increase awareness of what we are achieving in our society,’ he added, ‘by telling our powerful stories of innovation and standing up for science. It will require highlighting the possibilities of mRNA vaccines, gene therapy, crop editing , and the many other amazing technologies that we are investing in. mRNA took years and years to develop, but it arrived in time to treat Covid-19.’ Read Ted’s full remarks here.

Mainstage at the GA Life Sciences Summit
By Maria Thacker Goethe October 22, 2025
“Evolving FTC and DOJ policies leave investors and innovators navigating a cautious M&A landscape
October 6, 2025
Atlanta, GA — October 6 — Georgia Life Sciences today announced the launch of Vitals, a new podcast series developed in partnership with Cloudcast Media, a leader in branded podcast production. The series will spotlight the people, ideas, and innovations shaping the future of Georgia’s rapidly growing life sciences sector. Hosted by Georgia Life Sciences’ CEO, Maria Thacker Goethe, Vitals will feature in-depth conversations with scientists, entrepreneurs, investors, educators, policymakers, and patient advocates. Each episode will explore the challenges and opportunities facing Georgia’s life sciences ecosystem—spanning biopharma, medical technology, digital health, and advanced manufacturing. “Vitals gives us a powerful platform to showcase the remarkable work happening within our state,” said Maria Thacker Goethe. “By sharing these stories, we’re highlighting not only groundbreaking science but also the collaboration and talent that make Georgia such a vibrant hub for health innovation.” Cloudcast Media, known for its expertise in storytelling and high-quality podcast production, will bring industry insights and technical support to ensure the series reaches audiences across Georgia and beyond. “We’re proud to partner with Georgia Life Sciences on Vitals,” said Charles Parisi, Founder and CEO of Cloudcast. “This series will elevate the voices of innovators who are advancing science, improving patient outcomes, and building Georgia’s reputation as a global life sciences leader. We are very excited that Cloudcast Atlanta can play a role in supporting Maria and the impactful work of Georgia Life Sciences.” The first episode of Vitals launched today and is available on Apple Podcasts, Spotify, and other major streaming platforms, as well as through the Georgia Life Sciences website.
October 1, 2025
September 30, 2025 WASHINGTON, D.C. – John F. Crowley, President and CEO of the Biotechnology Innovation Organization (BIO) released the following statement on Most Favored Nation policies: "For too many years, Americans have subsidized the research and development necessary to bring newer and better medicines to patients around the world. As we saw with defense spending and NATO, the solution is not to weaken a strategically important American industry, but for other countries to pay their fair share. “Today’s announcement in the Oval Office highlights the problems with a drug delivery system where half of the cost of innovative medicines goes to middlemen and distributors, and where the supply chain distorts prices paid by the American people. We support a new framework that addresses the cost of medicines by simplifying the system - and making medicines directly available to patients. “But importing socialist price controls through most-favored nation policies fundamentally does not address the imbalance in international pricing for innovative medicines. MFN will not lower the out-of-pocket prices that most Americans pay for medicines. Even worse, it will jeopardize the entrepreneurial spirit and deter the capital necessary for a vibrant and essential American biotechnology industry to thrive and may cause most harm to small and midsize biotech companies, which are responsible for discovering more than half of all new treatments. “Without these biotech innovators and a free-market system, we risk slower scientific progress, decreased access to new medicines, compromised national security, fewer American jobs and perhaps most tragically, a diminished hope for those suffering with illness and disease. There are much better ways to address this problem than MFN.” ###
MORE POSTS